Abstract 123: Enhanced anti-tumor activity of the combination of entinostat and NKTR214 in renal and colon cancer tumor models
Lei Wang(Tang Hospital), Jonathan Zalevsky(Nektar Therapeutics (United States)), Peter Ordentlich(Kala Pharmaceuticals (United States)), Fei Chen(Wayne State University), Tingting Li(Shandong University)
Cited by 1
Related Papers
β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2
|The Journal of Cell Biology|2000|816
Enhanced antibody half-life improves in vivo activity
|Nature Biotechnology|2010|654
JNK and Tumor Necrosis Factor-α Mediate Free Fatty Acid-induced Insulin Resistance in 3T3-L1 Adipocytes
|Journal of Biological Chemistry|2005|403